Your browser doesn't support javascript.
loading
Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances.
Porter, Anna K; Kleinschmidt, Sarah E; Andres, Kara L; Reusch, Courtney N; Krisko, Ryan M; Taiwo, Oyebode A; Olsen, Geary W; Longnecker, Matthew P.
Afiliação
  • Porter AK; Ramboll U.S. Consulting, 3214 Charles B. Root Wynd, Suite 130, Raleigh, NC 27612, United States. Electronic address: aporter@ramboll.com.
  • Kleinschmidt SE; 3M Company, Corporate Occupational Medicine, St. Paul, MN 55144, United States.
  • Andres KL; 3M Company, Corporate Occupational Medicine, St. Paul, MN 55144, United States.
  • Reusch CN; 3M Company, Corporate Occupational Medicine, St. Paul, MN 55144, United States.
  • Krisko RM; 3M Company, Environment, Health, Safety and Product Stewardship, St. Paul, MN 55144, United States.
  • Taiwo OA; 3M Company, Corporate Occupational Medicine, St. Paul, MN 55144, United States.
  • Olsen GW; 3M Company, Corporate Occupational Medicine, St. Paul, MN 55144, United States.
  • Longnecker MP; Ramboll U.S. Consulting, 3214 Charles B. Root Wynd, Suite 130, Raleigh, NC 27612, United States.
Environ Int ; 169: 107537, 2022 11.
Article em En | MEDLINE | ID: mdl-36183490
ABSTRACT
Per- and polyfluoroalkyl substances (PFAS) are a broad class of synthetic chemicals; some are present in most humans in developed countries. Several studies have shown associations between certain PFAS, such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS), and reduced antibody concentration after vaccination against diseases such as Tetanus. Recent studies have reported associations between COVID-19 occurrence and exposure to certain types of PFAS. However, studies of antibody concentration after COVID-19 vaccination in relation to PFAS serum concentrations have not been reported. We examined COVID-19 antibody responses to vaccines and PFAS serum concentrations among employees and retirees from two 3M facilities, one of which historically manufactured PFOS, PFOA, and perfluorohexane sulfonic acid (PFHxS). Participants completed enrollment and follow-up study visits in the Spring of 2021, when vaccines were widely available. In total 415 participants with 757 observations were included in repeated measures analyses. Log-transformed concentrations of anti-spike IgG and neutralizing antibodies were modeled in relation to concentration of PFAS at enrollment after adjusting for antigenic stimulus group (9 groups determined by COVID-19 history and number and type of vaccination) and other variables. The fully adjusted IgG concentration was 3.45 percent lower (95% CI -7.03, 0.26) per 14.5 ng/mL (interquartile range) increase in PFOS; results for neutralizing antibody and PFOS were similar. For PFOA, PFHxS, and perfluorononanoic acid (PFNA), the results were comparable to those for PFOS, though of smaller magnitude. In our study data, the fully adjusted coefficients relating concentration of vaccine-induced antibodies to COVID-19 and interquartile range difference in serum concentration of PFOS, PFOA, PFHxS, and PFNA were inverse but small with confidence intervals that included zero. Our analysis showed that the coefficient for the four PFAS examined in detail was considerably affected by adjustment for antigenic stimulus group.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos Alcanossulfônicos / Poluentes Ambientais / Fluorocarbonos / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos Alcanossulfônicos / Poluentes Ambientais / Fluorocarbonos / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article